← SGLT2 inhibitors × glycemic control

TrialCardiovascular diabetology2016

Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.

Nobuya Inagaki et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT02220920. Its numbers are set against the trial’s posted results below.

What the trial testedrandomised · 146 people · 2016

Randomised comparison

Probably lowered glycemic control

−1.10percentage points−1.33 to −0.87

As reported

difference −1.10 %, 95% CI −1.33 to −0.87

Against the trial’s posted results

  • Same as the trial’s posted resultThis paper difference −1.10 (−1.33 to −0.87)Posted, primary outcome difference −1.10 (−1.33 to −0.87), p <0.001Change in HbA1c From Baseline

One number in the abstract

the abstract, start to end

… to the placebo-adjusted changes of -1.10 % (95 % CI, -1.33 to -0.87; p < …

← favours treatmentfavours comparator →
could be chance
Glycemic control
−1.10−1.33 to −0.87
SGLT2 inhibitorsGlycemic control

SGLT2 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.920.92 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

48 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT02220920phase 4146 enrolled2014this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 27316668